GPR6

Across TCGA pan-cancer cohorts, GPR6 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated GPR6 data layer compared with 3 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher GPR6 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated GPR6 expression acts as an unfavorable survival marker, although some lineages such as UCEC and PAAD show a favorable association.

LIHC, LUAD, and COAD are the cancer types where GPR6 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	II,III,IV	0.132	0.436	.003	75	view →
LUAD	OS	Tertile	IV	0.418	0.768	.002	57	view →
COAD	OS	Tertile	IV	0.082	0.659	<.001	57	view →
UCEC	OS	Tertile	IV	0.739	0.317	.012	36	view →
PAAD	DFS	Median	All	0.405	0.171	<.001	26	view →
LGG	DFS	Quartile	All	0.929	0.757	.002	20	view →
ACC	OS	Tertile	IV	0.327	0.633	.045	18	view →
ESCA	DFS	Tertile	All	0.232	0.773	.006	18	view →
BRCA	DFS	Quartile	IV	0.697	0.290	.016	10	view →
SKCM	DFS	Tertile	All	0.826	0.611	.021	3	view →
SCLC	DFS	Median	II,III,IV	0.562	0.346	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

GPR6–LIHC (DFS)

Open the LIHC breakdown →